

**March 2009 PBAC OUTCOMES - Reviews**

<b>DRUG AND FORM</b>	<b>DRUG USE AND TYPE</b>	<b>REASON FOR REVIEW</b>	<b>PBAC FINDING</b>
<p>CLOPIDOGREL HYDROGEN SULFATE, tablet, 75 mg (base), Iscover<sup>®</sup>, Bristol-Myers Squibb Pharmaceuticals; Plavix<sup>®</sup>, Sanofi-Aventis Australia Pty Ltd</p> <p>Review</p>	<p>Anti-platelet</p>	<p>To review the cost-effectiveness of clopidogrel in coronary artery stenting.</p>	<p>The PBAC recommended extending the listing of clopidogrel for use following stent insertion in patients without a prior history of Acute Coronary Syndrome (ACS) in combination with aspirin, and as monotherapy in those patients unable to tolerate aspirin. The PBAC considered that there is evidence that this is best clinical practice and noted that any increase in use is likely to be minimal following this listing.</p>